Aptahem organizes an online Sepsis seminar on World Sepsis Day 13 September
Aptahem AB develops drugs for the treatment of acute life-threatening conditions where Apta-1, the company's main candidate, is under development and intended as an emergency drug to prevent the occurrence of organ and tissue damage in patients suffering from sepsis.Every year, approx. 40,000 people suffer from sepsis in Sweden. Totally, worldwide between 47-50 million people are affected, of which approx. 11 million die from sepsis (www.globalsepsisalliance.org). To notice the WSD, Aptahem is arranging an online Sepsis Seminar on September 13 at 3.00-5.30 pm CET. The presentations will